Deep learning-based assessment of PD-L1 expression in NSCLC predicts outcome for patients treated with anti-PD-1 immunotherapy
BackgroundPD-L1 expression is widely used as a predictive biomarker for anti-PD-1 therapies in non-small cell lung cancer (NSCLC). However, its prognostic value remains controversial. Here, we investigated whether deep learning (DL) applied to PD-L1 im…